Jackson Thornton Wealth Management’s AbbVie ABBV Stock Holding History

Jackson Thornton Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,776	Closed	-$398K	–	287
2025 Q4	$398K	Buy	1,776 +297	+20%	+$67.7K	0.04%	143
2025 Q3	$342K	Buy	1,479 +24	+2%	+$4.89K	0.03%	159
2025 Q2	$276K	Buy	1,455 +82	+6%	+$15.2K	0.03%	92
2025 Q1	$238K	Buy	1,373 +173	+14%	+$33.6K	0.03%	80
2024 Q4	$213K	Buy	1,200 +2	+0.2%	+$368	0.03%	78
2024 Q3	$237K	Sell	1,198 -4	-0.3%	-$747	0.03%	56
2024 Q2	$206K	Sell	1,202 -29	-2%	-$4.8K	0.03%	53
2024 Q1	$224K	Buy	+1,231	New	+$212K	0.04%	48
2022 Q3	–	Sell	-1,446	Closed	-$221K	–	30
2022 Q2	$221K	Buy	1,446 +192	+15%	+$29.3K	0.06%	24
2022 Q1	$203K	Buy	+1,254	New	+$182K	0.05%	25

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jackson Thornton Wealth Management's ABBV Position: Q1 2026 in Review

Jackson Thornton Wealth Management sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 1,776 shares — an estimated $398K sold.

Jackson Thornton Wealth Management first reported a position in ABBV in Q1 2022 and held it in 10 quarters. The position peaked at $398K in Q4 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Jackson Thornton Wealth Management reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
Jackson Thornton Wealth Management sold 1,776 AbbVie shares in Q1 2026, an estimated $398K.
Jackson Thornton Wealth Management first reported a position in AbbVie in Q1 2022 and held it in 10 quarters.
Jackson Thornton Wealth Management's AbbVie position peaked at $398K in Q4 2025.
4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Jackson Thornton Wealth Management's 13F filing for Q1 2026, filed 29 Apr 2026.